TY - JOUR
T1 - Comprehensive Analysis of Low-Molecular-Weight Human Plasma Proteome Using Top-Down Mass Spectrometry
AU - Cheon, Dong Huey
AU - Nam, Eun Ji
AU - Park, Kyu Hyung
AU - Woo, Se Joon
AU - Lee, Hye Jin
AU - Kim, Hee Cheol
AU - Yang, Eun Gyeong
AU - Lee, Cheolju
AU - Lee, Ji Eun
N1 - Publisher Copyright:
© 2015 American Chemical Society.
PY - 2016/1/4
Y1 - 2016/1/4
N2 - While human plasma serves as a great source for disease diagnosis, low-molecular-weight (LMW) proteome (<30 kDa) has been shown to contain a rich source of diagnostic biomarkers. Here we employ top-down mass spectrometry to analyze the LMW proteoforms present in four types of human plasma samples pooled from three healthy controls (HCs) without immunoaffinity depletion and with depletion of the top two, six, and seven high-abundance proteins. The LMW proteoforms were first fractionated based on molecular weight using gel-eluted liquid fraction entrapment electrophoresis (GELFrEE). Then, the GELFrEE fractions containing up to 30 kDa were subjected to nanocapillary-LC-MS/MS, and the high-resolution MS and MS/MS data were processed using ProSightPC 3.0. As a result, a total of 442 LMW proteins and cleaved products, including those with post-translational modifications and single amino acid variations, were identified. From additional comparative analysis of plasma samples without immunoaffinity depletion between HCs and colorectal cancer (CRC) patients via top-down approach, tens of LMW proteoforms, including platelet factor 4, were found to show >1.5-fold changes between the plasma samples of HCs and CRC patients, and six of the LMW proteins were verified by Western blot analysis.
AB - While human plasma serves as a great source for disease diagnosis, low-molecular-weight (LMW) proteome (<30 kDa) has been shown to contain a rich source of diagnostic biomarkers. Here we employ top-down mass spectrometry to analyze the LMW proteoforms present in four types of human plasma samples pooled from three healthy controls (HCs) without immunoaffinity depletion and with depletion of the top two, six, and seven high-abundance proteins. The LMW proteoforms were first fractionated based on molecular weight using gel-eluted liquid fraction entrapment electrophoresis (GELFrEE). Then, the GELFrEE fractions containing up to 30 kDa were subjected to nanocapillary-LC-MS/MS, and the high-resolution MS and MS/MS data were processed using ProSightPC 3.0. As a result, a total of 442 LMW proteins and cleaved products, including those with post-translational modifications and single amino acid variations, were identified. From additional comparative analysis of plasma samples without immunoaffinity depletion between HCs and colorectal cancer (CRC) patients via top-down approach, tens of LMW proteoforms, including platelet factor 4, were found to show >1.5-fold changes between the plasma samples of HCs and CRC patients, and six of the LMW proteins were verified by Western blot analysis.
KW - biomarker
KW - cleaved products
KW - colorectal cancer (CRC)
KW - gel-eluted liquid fraction entrapment electrophoresis (GELFrEE)
KW - human plasma
KW - low-molecular-weight (LMW) plasma proteins
KW - post-translational modification (PTM)
KW - single amino acid variation (SAAV)
KW - top-down mass spectrometry
UR - http://www.scopus.com/inward/record.url?scp=84953238347&partnerID=8YFLogxK
U2 - 10.1021/acs.jproteome.5b00773
DO - 10.1021/acs.jproteome.5b00773
M3 - Article
C2 - 26576621
AN - SCOPUS:84953238347
SN - 1535-3893
VL - 15
SP - 229
EP - 244
JO - Journal of Proteome Research
JF - Journal of Proteome Research
IS - 1
ER -